Insight Brief
August 08, 2017

Minimal Residual Disease: Finding the Right Test for the New Definition of Remission

Measurement of Residual Disease for improved oncology trial outcomes
Today, measurement of minimal residual disease (MRD) is one of the most reliable predictors of treatment outcomes for leukemia and lymphoma, and myeloma.

There are multiple measurement approaches for MRD testing and key criteria to consider when selecting the right tool for MRD detection. 

Download this insight brief to discover what factors make an MRD test most effective plus explore the pros and cons of various MRD measurement approaches.

Mark Edinger, Director, Scientific Advisor, Flow Cytometry
Victor Weigman, Director, Translational Genomics
Patrick Hurban, Scientific Advisor; Senior Director and Global Head, Translational Genomics
Alan Wookey, Global Science Lead, Companion Diagnostics & Scientific Advisor, Oncology
Franklin Sederat, Director of Homatopathology
Patrice Hugo, Chief Scientific Officer

Related Services:
Minimal Residual Disease Detection: Key Considerations for Clinical Development in Oncology

What you should know for your clinical development program

Global Flow Cytometry Services

Unique global flow cytometry services are designed to meet your clinical trial needs

Genomic Based Solutions for Your Immuno-oncology Drug Development Needs

Genomics-based biomarker approach

Clinical Trials Laboratories in the Immuno-Oncology Setting

Increased demands lead to increased opportunities

The Power of the Central Laboratory for Immuno-Oncology Drug Development

Read More